{
  "items": "20",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "Why Conduit Pharmaceuticals Inc. Equity Warrant stock is seen as undervalued - Weekly Trade Report & AI Forecast Swing Trade Picks",
      "url": "https://ulpravda.ru/key-takeaways/Why-Conduit-Pharmaceuticals-Inc.-Equity-Warrant-stock-is-seen-as-undervalued",
      "time_published": "20251219T040908",
      "authors": [
        "NULL"
      ],
      "summary": "This article is primarily a collection of various irrelevant phrases and repeated financial marketing slogans, with scattered sentences about a public library, a girl's medical treatment crisis, and a travel agency's sudden closure due to alleged fraud. The intended primary subject, Conduit Pharmaceuticals Inc. Equity Warrant stock being undervalued, is merely mentioned in the title and intro paragraphs but not discussed within the content. The article frequently intersperses financial planning slogans about starting with $100 for high returns.",
      "banner_image": "https://asserts.btccryptcion.shop/asserts/english/images/watermark_20250427_3_w3.jpg",
      "source": "\u0423\u043b\u043f\u0440\u0430\u0432\u0434\u0430",
      "category_within_source": "General",
      "source_domain": "\u0423\u043b\u043f\u0440\u0430\u0432\u0434\u0430",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.948751"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.729760"
        }
      ],
      "overall_sentiment_score": 0.4169,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CDT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.401144",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "CONDUIT PHARMACEUTICALS INC. SEC 10-K Report",
      "url": "https://www.tradingview.com/news/tradingview:69775c60654a1:0-conduit-pharmaceuticals-inc-sec-10-k-report/",
      "time_published": "20251102T112502",
      "authors": [],
      "summary": "Conduit Pharmaceuticals Inc. has released its annual 10-K report, detailing its financial performance, business operations, and strategic initiatives. The report highlights significant increases in R&D and G&A expenses, driven by upfront payments and operational growth, alongside substantial net losses since inception. The company's strategy involves developing clinical assets from pharmaceutical companies using AI, focusing on unmet medical needs, while facing challenges like financial sustainability and regulatory risks.",
      "banner_image": null,
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.914061"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.814814"
        },
        {
          "topic": "finance",
          "relevance_score": "0.701463"
        },
        {
          "topic": "economy_macro",
          "relevance_score": "0.646165"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.622354"
        }
      ],
      "overall_sentiment_score": -0.309603,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CDT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.307315",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "CDT Equity Increases Bitcoin Holding - MarketScreener",
      "url": "https://www.marketscreener.com/news/cdt-equity-increases-bitcoin-holding-ce7d5addda8bfe23",
      "time_published": "20251017T123007",
      "authors": [],
      "summary": "CDT Equity Inc. has announced a new acquisition of 9.25648743 Bitcoin for $1,005,000, bringing its total Bitcoin holdings to 17.9090111 BTC. This move is part of the company's cryptocurrency treasury reserve strategy, aimed at diversifying its balance sheet and enhancing long-term shareholder value through digital asset accumulation. The company emphasizes a disciplined and opportunistic approach to capital management, aligning with institutional adoption of digital assets and capitalizing on market corrections.",
      "banner_image": "https://ml.globenewswire.com/media/MjUyNmVlZDItY2UzMC00YTUzLTk0YTctMzUyMjlhYTljMjMxLTEyNzQxMDItMjAyNS0xMC0xNy1lbg==/tiny/CDT-Equity-Inc-.png",
      "source": "MarketScreener",
      "category_within_source": "General",
      "source_domain": "MarketScreener",
      "topics": [
        {
          "topic": "blockchain",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.927721"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.824606"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.620655"
        },
        {
          "topic": "finance",
          "relevance_score": "0.529780"
        }
      ],
      "overall_sentiment_score": 0.042183,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CDT",
          "relevance_score": "0.347793",
          "ticker_sentiment_score": "0.010335",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CDT Equity Increases Bitcoin Holding - Stock Titan",
      "url": "https://www.stocktitan.net/news/CDT/cdt-equity-increases-bitcoin-hkcnx1qsk0ld.html",
      "time_published": "20251017T123000",
      "authors": [],
      "summary": "CDT Equity Inc. (Nasdaq: CDT) announced on October 17, 2025, the acquisition of 9.25648743 Bitcoin (BTC) for $1,005,000, at an average price of $108,301.75 per BTC. This purchase increases CDT's total Bitcoin holdings to 17.9090111 BTC, aligning with its cryptocurrency treasury reserve strategy to diversify its balance sheet and enhance long-term shareholder value. The company, also a biopharmaceutical development firm, views this as a disciplined approach to capital management amidst growing institutional adoption of digital assets.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "blockchain",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.844771"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.507031"
        }
      ],
      "overall_sentiment_score": 0.031492,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CDT",
          "relevance_score": "0.323592",
          "ticker_sentiment_score": "0.036199",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Conduit Pharmaceuticals Rebrands to CDT Equity Inc.",
      "url": "https://www.theglobeandmail.com/investing/markets/stocks/CDT/pressreleases/34030995/conduit-pharmaceuticals-rebrands-to-cdt-equity-inc/",
      "time_published": "20250809T040234",
      "authors": [
        "NULL"
      ],
      "summary": "Conduit Pharmaceuticals has rebranded to CDT Equity Inc., reflecting a strategic shift towards leveraging AI and scientific innovation to enhance therapeutic assets. Stockholders approved an amendment to the 2023 Stock Incentive Plan, authorized additional shares, and appointed James Bligh as the permanent CFO, aiming to unlock value and explore new market opportunities. The company focuses on developing treatments for inflammatory disorders, autoimmune diseases, and male infertility.",
      "banner_image": "NULL",
      "source": "The Globe and Mail",
      "category_within_source": "General",
      "source_domain": "The Globe and Mail",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.915089"
        },
        {
          "topic": "finance",
          "relevance_score": "0.731184"
        },
        {
          "topic": "technology",
          "relevance_score": "0.615568"
        }
      ],
      "overall_sentiment_score": -0.07091,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CDT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.310270",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "WBD",
          "relevance_score": "0.646674",
          "ticker_sentiment_score": "-0.445689",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Conduit Pharmaceuticals moves to Nasdaq Capital Market",
      "url": "https://www.investing.com/news/company-news/conduit-pharmaceuticals-moves-to-nasdaq-capital-market-93CH-4059680",
      "time_published": "20250522T083300",
      "authors": [
        "Investing.com"
      ],
      "summary": "Conduit Pharmaceuticals Inc. (NASDAQ:CDT) has received approval to transfer its common stock listing to the Nasdaq Capital Market, effective May 23, 2025, after meeting bid price and equity requirements. The company, which uses AI in drug development for Phase 2-ready assets and aims for licensing exits, faces challenges with a $3.76 million market cap and weak financial health despite its innovative business model. This move follows recent actions to comply with Nasdaq listing standards, including a 1-for-15 reverse stock split and continued R&D in autoimmune diseases.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_pile_69x52._800x533_L_1419494209.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.839943"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.916231"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.943893"
        }
      ],
      "overall_sentiment_score": 0.088268,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CDT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.238463",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "WBD",
          "relevance_score": "0.610048",
          "ticker_sentiment_score": "0.132632",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PSKY",
          "relevance_score": "0.601128",
          "ticker_sentiment_score": "0.132821",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WRB",
          "relevance_score": "0.616788",
          "ticker_sentiment_score": "0.132423",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VST",
          "relevance_score": "0.626889",
          "ticker_sentiment_score": "0.131927",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Conduit Pharmaceuticals Inc. Announces 1-for-15 Reverse Stock Split Approval",
      "url": "https://www.nasdaq.com/articles/conduit-pharmaceuticals-inc-announces-1-15-reverse-stock-split-approval",
      "time_published": "20250516T084000",
      "authors": [
        "NULL"
      ],
      "summary": "Conduit Pharmaceuticals Inc. has announced a 1-for-15 reverse stock split, approved by its board and stockholders, to become effective on May 19, 2025. This action will combine every fifteen shares into one, with trading on a split-adjusted basis under the ticker \"CDT\" beginning May 20, 2025. The company expects this move to potentially enhance its stock price and attract institutional investors, despite common associations of reverse splits with underlying stock performance issues.",
      "banner_image": "NULL",
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.944170"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.918249"
        }
      ],
      "overall_sentiment_score": -0.291056,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CDT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.263027",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Conduit Pharma Sets 15:1 Reverse Split: Shares Drop to 755,900 Starting May 20",
      "url": "https://www.stocktitan.net/news/CDT/conduit-pharmaceuticals-inc-announces-reverse-stock-0s7253qkhiwt.html",
      "time_published": "20250516T083000",
      "authors": [
        "NULL"
      ],
      "summary": "Conduit Pharmaceuticals Inc. (Nasdaq: CDT) has announced a 1-for-15 reverse stock split, effective May 19, 2025, at 5:00 pm ET, with split-adjusted trading commencing May 20, 2025. This action, approved by stockholders, will reduce the outstanding shares to approximately 755,900 and aims to help meet Nasdaq listing requirements. The company's stock price declined 4.41% on the publication day, indicating a negative market reaction.",
      "banner_image": "NULL",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.935811"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.816369"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.742532"
        }
      ],
      "overall_sentiment_score": -0.260089,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CDT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.286737",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Serial Entrepreneur with $7B+ Exit Track Record Takes CEO Role at Conduit Pharma",
      "url": "https://www.stocktitan.net/news/CDT/conduit-pharmaceuticals-announces-leadership-19s99lgea7sr.html",
      "time_published": "20250416T060921",
      "authors": [],
      "summary": "Conduit Pharmaceuticals announced founder Dr. Andrew Regan has taken over as CEO, replacing Dr. David Tapolczay, who will now focus on out-licensing deals for tapinarof patents. Dr. Regan, known for multiple billion-dollar ventures, aims to maximize shareholder value through licensing opportunities, new 20-year Composition-of-Matter patents, and AI-driven drug repurposing. The company also noted a 12.97% stock decline on the news day, reflecting a negative market reaction despite the strategic shift.",
      "banner_image": "https://ml.globenewswire.com/media/N2ZmNTFlM2QtYjFjMy00MTU4LWE1ZGEtMmJkMDY1NThkNjBkLTEyNzQxMDItMjAyNS0wNC0xNi1lbg==/tiny/Conduit-Pharmaceuticals.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.932218"
        },
        {
          "topic": "finance",
          "relevance_score": "0.748288"
        }
      ],
      "overall_sentiment_score": -0.380534,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CDT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.382906",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Conduit Pharma\u2019s Surge: What\u2019s Fueling It?",
      "url": "https://stockstotrade.com/news/conduit-pharmaceuticals-inc-cdt-news-2025_04_11/",
      "time_published": "20250411T100300",
      "authors": [
        "Tim Bohen",
        "Ben Sturgill",
        "Ellis Hobbs"
      ],
      "summary": "Conduit Pharmaceuticals' stock surged by 12.62% due to a new US patent for its drug candidate AZD1656, an expanded partnership using machine learning for drug development, and a share buyback program. Despite negative operating cash flow, the company's strategic moves and intellectual property expansion suggest long-term growth potential, attracting risk-takers in the biotech sector. These developments, along with its focus on autoimmune disease treatments, indicate cautious optimism for its future performance.",
      "banner_image": "NULL",
      "source": "StocksToTrade",
      "category_within_source": "General",
      "source_domain": "StocksToTrade",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.936647"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.820574"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.746269"
        }
      ],
      "overall_sentiment_score": 0.351218,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CDT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.404900",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "CRL",
          "relevance_score": "0.649651",
          "ticker_sentiment_score": "0.277037",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Conduit Pharma Advances Lupus Treatment Pipeline with Key Development Milestones | CDT Stock News",
      "url": "https://www.stocktitan.net/news/CDT/conduit-pharmaceuticals-provides-research-and-development-update-on-wkebn8d5wwee.html",
      "time_published": "20250319T060916",
      "authors": [
        "NULL"
      ],
      "summary": "Conduit Pharmaceuticals announced significant progress in its R&D pipeline for AZD1656, AZD5658, and AZD5904, focusing on autoimmune diseases like lupus. The company has partnered with Charles River Laboratories for preclinical studies of glucokinase inhibitors, with results expected in Q2 2025, and is designing a Phase II clinical trial for AZD1656 targeting systemic lupus erythematosus and ANCA-associated vasculitis. Key milestones include granted composition-of-matter patents for AZD1656 Cocrystals in Japan and Australia, and ongoing formulation optimization efforts with Agility Life Sciences to develop novel solid oral-dosage forms.",
      "banner_image": "https://www.globenewswire.com/newsroom/ti?nf=OTM5NzA3MSM2ODEzMzk4IzIyNjI1NTI=",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.949797"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.644185"
        },
        {
          "topic": "finance",
          "relevance_score": "0.633469"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.621714"
        }
      ],
      "overall_sentiment_score": 0.284046,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CDT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.257335",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CRL",
          "relevance_score": "0.625784",
          "ticker_sentiment_score": "0.319060",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Conduit Pharmaceuticals Enters Strategic Agreement with Agility Life Sciences",
      "url": "https://www.contractpharma.com/breaking-news/conduit-pharmaceuticals-enters-strategic-agreement-with-agility-life-sciences/",
      "time_published": "20250122T000000",
      "authors": [
        "Charlie Sternberg"
      ],
      "summary": "Conduit Pharmaceuticals Inc. has entered into a strategic services agreement with Agility Life Sciences to develop new solid oral-dosage form products for its autoimmune pipeline. This collaboration aims to leverage Conduit's newly established composition-of-matter intellectual property for its autoimmune assets to create enhanced oral dosage forms, maximizing market potential and strengthening market protection. The dual-track approach involves developing proprietary formulations in parallel with ongoing clinical trials, optimizing assets for future licensing opportunities.",
      "banner_image": null,
      "source": "Contract Pharma",
      "category_within_source": "General",
      "source_domain": "Contract Pharma",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.933377"
        },
        {
          "topic": "manufacturing",
          "relevance_score": "0.715881"
        }
      ],
      "overall_sentiment_score": 0.418867,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CDT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.415841",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Conduit Pharmaceuticals faces Nasdaq delisting over price, votes for reverse split",
      "url": "https://www.investing.com/news/sec-filings/conduit-pharmaceuticals-faces-nasdaq-delisting-over-price-votes-for-reverse-split-93CH-3785914",
      "time_published": "20241221T204900",
      "authors": [
        "Investing.com"
      ],
      "summary": "Conduit Pharmaceuticals (NASDAQ:CDT) is facing potential delisting from Nasdaq due to its share price falling below the minimum bid requirement and triggering the exchange's Low Priced Stocks Rule. In response, the company's stockholders have approved a reverse stock split to increase the per-share price and regain compliance, while the company plans to request a hearing with the Nasdaq Hearings Panel to delay the delisting action. The company has also announced several recent financial and corporate developments, including new funding, an at-the-market offering, and the appointment of a new director.",
      "banner_image": null,
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.930979"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.843991"
        },
        {
          "topic": "finance",
          "relevance_score": "0.708163"
        }
      ],
      "overall_sentiment_score": -0.732573,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CDT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.742842",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Conduit Pharmaceuticals Partners with SARBORG Limited to Enhance Drug Development with AI and Cybernetics Technology",
      "url": "https://www.nasdaq.com/articles/conduit-pharmaceuticals-partners-sarborg-limited-enhance-drug-development-ai-and",
      "time_published": "20241212T074100",
      "authors": [
        "None for Quiver Quantitative"
      ],
      "summary": "Conduit Pharmaceuticals has partnered with SARBORG Limited to integrate an advanced AI and cybernetics platform into its drug development processes. This collaboration aims to improve efficiency, reduce costs, and accelerate timelines in areas like drug repurposing, discovery, and clinical trial monitoring. Conduit will gain access to predictive models and real-time data dashboards, securing a competitive edge and long-term innovation in the pharmaceutical industry.",
      "banner_image": null,
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.918800"
        },
        {
          "topic": "technology",
          "relevance_score": "0.824412"
        }
      ],
      "overall_sentiment_score": 0.4841,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CDT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.460433",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Conduit Pharmaceuticals Strengthens Board with 30-Year Investment Banking Veteran Simon Fry",
      "url": "https://www.stocktitan.net/news/CDT/conduit-pharmaceuticals-announces-appointment-of-simon-fry-to-board-28iqfk1j1xh3.html",
      "time_published": "20241119T163000",
      "authors": [],
      "summary": "Conduit Pharmaceuticals (Nasdaq: CDT) has announced the appointment of Simon Fry, a seasoned investment banking veteran with over 30 years of experience, to its Board of Directors, effective December 18, 2024. Fry, with a background at Crosby Asset Management, Nomura, and Credit Suisse First Boston, will serve on both the Audit Committee and Compensation Committee. His extensive expertise in capital markets and strategic asset management is expected to significantly contribute to Conduit's growth objectives and enhance shareholder value.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.834997"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.733303"
        }
      ],
      "overall_sentiment_score": 0.455778,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CDT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.469729",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "4 Stocks Moving Sharply Before the Market Opens: CDT, XPON, WENA, ADD",
      "url": "https://247wallst.com/investing/2024/08/08/4-stocks-moving-sharply-before-the-market-opens/",
      "time_published": "20240808T083700",
      "authors": [
        "Joshua Rodriguez"
      ],
      "summary": "This article highlights four stocks experiencing significant premarket movement: Conduit Pharmaceuticals (CDT) soared on an AstraZeneca licensing agreement, Expion360 (XPON) bounced back after a public offering announcement, ANEW MEDICAL (WENA) climbed due to new patent issuances, and Color Star Technology (ADD) fell sharply amidst speculation and pump-and-dump concerns. Investors are advised to exercise caution with speculative stocks like ADD.",
      "banner_image": null,
      "source": "24/7 Wall St.",
      "category_within_source": "General",
      "source_domain": "24/7 Wall St.",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.941095"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.807092"
        },
        {
          "topic": "technology",
          "relevance_score": "0.617590"
        }
      ],
      "overall_sentiment_score": 0.418146,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CDT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.429041",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "EXCLUSIVE: Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets",
      "url": "https://finance.yahoo.com/news/exclusive-penny-stock-conduit-pharmaceuticals-100021963.html",
      "time_published": "20240808T000000",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Conduit Pharmaceuticals has signed an exclusive licensing agreement with AstraZeneca for multiple assets, including HK-4 glucokinase activators AZD1656 and AZD5658, and myeloperoxidase inhibitor AZD5904. Conduit plans to initiate Phase 2 clinical trials for AZD1656 and AZD5658 in autoimmune disorders in 2024. AstraZeneca will receive Conduit shares, sublicense revenues, and retain a right of first negotiation for future development and commercialization of the licensed compounds.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.942028"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.806439"
        }
      ],
      "overall_sentiment_score": 0.346069,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CDT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.342898",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Conduit acquires three first-in-class assets from AstraZeneca",
      "url": "https://www.pharmaceutical-technology.com/news/conduit-acquires-three-first-in-class-assets-from-astrazeneca/",
      "time_published": "20240808T000000",
      "authors": [
        "Jenna Philpott"
      ],
      "summary": "Conduit Pharmaceuticals has acquired three first-in-class assets from AstraZeneca, including two HK-4 glucokinase activators (AZD1656 and AZD5658) and a myeloperoxidase inhibitor (AZD5904). Conduit plans to advance AZD1656 and AZD5658 into Phase II testing for autoimmune disorders and AZD5904 for idiopathic male infertility, leveraging AstraZeneca's prior Phase I clinical trial data. This acquisition significantly boosted Conduit's stock price by 123% following the announcement.",
      "banner_image": null,
      "source": "Pharmaceutical Technology",
      "category_within_source": "General",
      "source_domain": "Pharmaceutical Technology",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.919695"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.947443"
        }
      ],
      "overall_sentiment_score": 0.422292,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CDT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.434390",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Conduit Pharmaceuticals Names Dr. Joanne Holland as Chief Scientific Officer",
      "url": "https://www.contractpharma.com/breaking-news/conduit-pharmaceuticals-names-dr-joanne-holland-as-chief-scientific-officer/",
      "time_published": "20240320T000000",
      "authors": [
        "Charlie Sternberg"
      ],
      "summary": "Conduit Pharmaceuticals has appointed Dr. Joanne Holland as Chief Scientific Officer, leveraging her 20 years of experience in drug development and intellectual property related to solid-form technology. Concurrently, the company engaged intellectual property attorney Jeffrey Lindeman as a Consultant to advise on IP strategies for their solid-form candidates. This strategic move aims to optimize the value of Conduit's existing IP assets and foster new intellectual property creation, positioning the company for future out-licensing opportunities.",
      "banner_image": null,
      "source": "Contract Pharma",
      "category_within_source": "General",
      "source_domain": "Contract Pharma",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.915747"
        }
      ],
      "overall_sentiment_score": 0.288809,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CDT",
          "relevance_score": "0.979144",
          "ticker_sentiment_score": "0.435448",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.684203",
          "ticker_sentiment_score": "0.149618",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Conduit Pharmaceuticals Opens New Lab Space in Cambridge, UK",
      "url": "https://www.contractpharma.com/breaking-news/conduit-pharmaceuticals-opens-new-lab-space-in-cambridge-uk/",
      "time_published": "20240311T000000",
      "authors": [
        "Charlie Sternberg"
      ],
      "summary": "Conduit Pharmaceuticals Inc. has opened a new laboratory space in Cambridge, UK, to expand its portfolio, enhance development capabilities, and grow its intellectual property. The Cambridge lab will focus on strengthening IP using solid form technology and will serve as the nucleus for the company's workstream management platform, integrating scientific expertise with AI tools to streamline operations. This move reinforces Conduit's commitment to pharmaceutical innovation within a leading global life sciences hub.",
      "banner_image": null,
      "source": "Contract Pharma",
      "category_within_source": "General",
      "source_domain": "Contract Pharma",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.929352"
        },
        {
          "topic": "real_estate",
          "relevance_score": "0.635819"
        },
        {
          "topic": "finance",
          "relevance_score": "0.616654"
        },
        {
          "topic": "technology",
          "relevance_score": "0.645480"
        }
      ],
      "overall_sentiment_score": 0.496359,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CDT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.467402",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    }
  ]
}